The purpose of this research was to develop a matrix-type transdermal therapeutic system containing an antihypertensive drug, atenolol (ATL), with different concentrations of hydrophobic polymers like Eudragit RL-100 (ERL-100) and Eudragit RS-100 (ERS-100) by the solvent evaporation technique. Different concentrations of oleic acid (OA) were used to enhance the transdermal permeation of ATL. The physicochemical compatibility of the drug and the polymers was also studied by differential scanning calorimetry (DSC) and infrared (IR) spectroscopy. The results suggested no physicochemical incompatibility between the drug and the polymers. Formulated transdermal films were physically evaluated with regard to thickness, weight variation, flatness, drug content, folding endurance, % moisture uptake and % moisture content. All prepared formulations indicated good physical stability. In-vitro permeation studies of formulations were performed by using Franz diffusion cells. The results followed Higuchi kinetics, and the mechanism of release was diffusion-mediated. Formulation prepared with ERL 100 polymer containing permeation enhancer showed best in-vitro skin permeation through rat skin as compared with all other formulations.
Loading....